SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending as it unveils new AI chips targeting the data center market, aiming to compete with Nvidia and AMD. The community is discussing the potential impact of this move on the semiconductor landscape, with some anticipating significant growth for Qualcomm while others suggest increased competition may signal a sector cooldown. Bullish sentiment appears to be fueled by raised price targets and anticipation of a breakthrough in the AI chip world.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the OG meme coin, emphasizing its cultural significance and a return to the 'trenches' of meme creation. Community members express strong conviction and belief in the project, highlighting its organic growth and potential to disrupt the industry. The focus remains on community, memes, and shared enthusiasm.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending amid discussions about a potential acquisition of Larvotto Resources and its impact on the company's valuation. The community is weighing the potential benefits of the deal against concerns about share dilution, while also debating the significance of U.S.-China trade relations and antimony's role as a critical mineral independent of rare earth dynamics.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia is trending downwards following a self-imposed pause in late-stage clinical trials due to liver enzyme elevations in a patient, sparking community debate about the severity and implications of the event. Some investors view the dip as a buying opportunity, citing the potential for trial resumption and the company's long-term prospects in gene editing, while others are concerned about the potential impact on the company's future.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending as chatter revolves around a Trump Jr.-linked drone company securing a Pentagon contract and community members are actively discussing the implications of this contract, along with future targets based on chart analysis. Some traders are speculating on the potential for further government contracts and the overall heating up of the drone sector, while others point to the company's connection to the Trump family as a source of both opportunity and concern. Community members are closely watching for news and volume expansion that could force chasers through resistance levels.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors weigh the impact of potential US-China trade negotiations on rare earth elements and uranium. Community discussions revolve around large call option sweeps, a possible government stake, and the company's diversified capabilities. Recent news, including a joint venture in Australia, has also fueled speculation about the stock's near-term direction.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to its upcoming PDUFA date for Revuforj, with community members weighing in on the potential FDA decision and its impact on the stock. Discussions include the drug's market potential, comparisons to competitor KURA, and speculation about a potential buyout. Some traders are also highlighting the high short interest and potential for a squeeze.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings (CLIK) is trending as traders discuss its potential for a short squeeze, fueled by strong revenue growth and a small float. Community members are actively speculating on price targets, while also closely watching the stock's consolidation patterns. Some traders are also looking at it as a sympathy play with other HK stocks.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics (RR) is trending right now because of its new partnership with the Vegas Golden Knights and excitement around its upcoming humanoid robot reveal at the NVIDIA GTC conference. People are talking about how this could be a big step forward for AI and robotics. Some investors think the company could grow a lot in the future, while others are cautious because the stock might be unstable in the short term.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders weigh the potential for continued gains in the semiconductor sector against concerns of overvaluation and geopolitical risks. Community members are actively discussing entry and exit points, with some anticipating a pullback while others remain bullish, citing strong demand and potential benefits from AI-related developments. News around trade tensions, earnings reports from key semiconductor companies, and broader market sentiment are also influencing the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.</li><li>Prescription Drug User Fee Act decision date is set for April 10, 2026.</li><li>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4.</li></ul>Replimune Group Inc.(REPL) on Monday announced that it has cleared a major regulatory hurdle after the U.S. Food and Drug Administration (FDA) accepted its resubmitted Biologics License Application (BLA) for RP1, a treatment for advanced melanoma.The FDA has set April 10, 2026, as the Prescription Drug User Fee Act (PDUFA) target action date for this Class II resubmission.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/REPL">Replimune stock</a>&nbsp;traded over 98% higher on Monday morning and was the third most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day while message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">What Is RP1?</h2>RP1 is Replimune’s lead therapy candidate. It is derived from a modified herpes simplex virus, engineered to enhance tumor cell destruction and stimulate the body’s immune system against cancer. The therapy is designed with a fusogenic protein (GALV-GP R-) and GM-CSF to amplify both tumor-killing activity and the immune response.<blockquote>“RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma, who have progressed on PD-1 based therapy."- Sushil Patel, CEO, Replimune.</blockquote>The BLA resubmission follows several months of engagement between the company and the agency. Replimune worked to incorporate additional clinical data, detailed analyses and supporting documentation to address regulatory concerns.<h2 class="st-heading-2">What Are Analysts Saying?</h2>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4, according to TheFly. The firm sees the FDA’s quick response after a Type A meeting as an encouraging sign, suggesting the agency is open to the updated application with the new data included.Leerink analyst Jonathan Chang raised the firm’s rating to ‘Outperform’ from ‘Market Perform’ and lifted the price target to $13 from $3, expressing renewed confidence in RP1.&nbsp;Replimune stock has lost over 14% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sealsq-stock-jumps-13-today-company-s-first-chip-with-built-in-post-quantum-encryption-draws-attention/ch6CDEMR3Yn">SEALSQ Stock Jumps 13% Today: Company’s First Chip With Built-In Post-Quantum Encryption Draws Attention</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

What Is Driving Replimune Stock’s 98% Surge Today? 

FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.

Equity

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S. Food and Drug Administration. Shares of the company slumped 42% at the time of writing.The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.The company subsequently requested a meeting with the agency to push for approval of RP1. “We remain steadfastly committed to patient access while we work with the FDA to secure regulatory approval for RP1, however, without accelerated approval based on the current application, continuation of the RP1 program in advanced melanoma, including the phase 3 confirmatory trial, will not be viable,” CEO Sushil Patel said earlier this month.However, on Thursday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.replimune.com/news-releases/news-release-details/replimune-provides-update-following-type-meeting-fda">stated</a> that it had completed a meeting with the FDA on September 16 regarding the letter pertaining to the application for approval of RP1. The company stated that it is evaluating the feedback from the FDA to determine its next steps, and the path forward under the accelerated approval pathway has not yet been determined.“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” Patel reiterated on Thursday.RP1 is Replimune’s lead product candidate. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:571/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_11_25_42_AM_png_83a21ea942.webp" alt="REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="571" height="64"><figcaption>REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that a strategic review announcement is due in the coming months.<stembedurl>https://stocktwits.com/Bakhmutbull2/message/629140552</stembedurl>A more optimistic user, however, said that RP1 remains “a therapy to watch” for melanoma patients.<stembedurl>https://stocktwits.com/sousayuri/message/629114614</stembedurl>REPL stock is down by about 73% this year and by about 70% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-healthcare-reportedly-eyes-selling-stake-in-china-unit/chDcxTmR3bI">GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Replimune Stock Plunged 42% Today – Here’s Why

The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action. 

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of...

Retail&nbsp;trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral’, citing the sudden resignation of Vinay Prasad, former head of the FDA’s biologics division, as a key development that could improve the outlook for RP1, the company’s lead oncolytic immunotherapy candidate.The stock more than doubled Wednesday, closing up 101% at $7.55.Cantor analyst Li Watsek said the FDA’s Complete Response Letter (CRL) issued on July 22 for RP1 in combination with nivolumab was likely influenced by senior leadership, possibly Prasad, overruling the agency’s review team.&nbsp;Watsek sees Prasad’s exit as “removing a major obstacle” and believes the odds of RP1 receiving accelerated approval have “greatly improved.” Cantor expects Replimune shares could return to pre-CRL levels above $12 if the decision is overturned.BMO Capital analyst Evan Seigerman&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">also said</a> Prasad’s departure is a net positive for the biopharma sector, noting that a new FDA biologics director is “likely to be more permissive of innovation.” While BMO remains uncertain whether RP1 will be reconsidered, the firm expects shares to rally meaningfully on the change.<a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">Prasad stepped down</a> just two months into his role leading the FDA’s biologics division, after facing growing backlash over how he handled Sarepta’s Elevidys, the only approved gene therapy for Duchenne muscular dystrophy.Earlier this month, Prasad and FDA Commissioner Marty Makary asked Sarepta to halt shipments of Elevidys after three children who received the therapy died, including two from liver failure.&nbsp;The move ignited backlash from patient advocates and conservative media, who slammed the agency for standing in the way of what many families see as a last hope for kids battling a fatal condition.&nbsp;Replimune stated that the CRL for RP1 cited the Ignyte Phase 1/2 trial as lacking the rigor to support approval, due to heterogeneity in the patient population and concerns regarding the confirmatory study design. No safety issues were raised.&nbsp;The company plans to request a Type A meeting with the FDA to explore a path forward for accelerated approval.CEO Sushil Patel expressed surprise at the CRL, noting that the issues raised&nbsp;had not been&nbsp;discussed during the mid- and late-cycle reviews. RP1, engineered from a herpes simplex virus, is designed to directly kill tumors and trigger a systemic immune response.&nbsp;It’s the lead program in Replimune’s proprietary RPx platform, which the company believes can work&nbsp;independently or&nbsp;in conjunction with other cancer therapies.On Stocktwits, retail sentiment for Replimune was ‘extremely bullish’ late Wednesday amid a 1,038% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/REPL">Replimune’s stock</a> has declined nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around Replimune Group (REPL) surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral.’ (Photo credit: Getty Images)

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval

Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was based on trial design concerns.

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Replimune, Inc. (<a class="mention" data-mention="$REPL" data-symbol-id="REPL" href="https://stocktwits.com/symbol/REPL" target="_blank">$REPL</a>) shares spiked higher in Thursday’s after-hours session after the small-cap biopharma developing oncolytic immunotherapies, provided a key regulatory update for its combo therapy candidate to treat skin cancer, lifting retail sentiment.The Woburn, Mass.-based clinical-stage biopharma said after the market closed that it has submitted a biologic license application (BLA) for RP1, aka vusolimogene oderparepvec, -&nbsp; its lead immulytic product candidate, in combination with Bristol-Myers Squibb Co.’s (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">$BMY</a>) Opdivo, for advanced melanoma patients who have been previously treated with anti-PD1 therapies.Anti-PD1 therapy is currently the standard of care for several types of cancer.RP1 is based on a proprietary new strain of the Herpes simplex virus engineered to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.The regulatory filing has been done under the accelerated approval pathway, which expedites approval for drugs to treat unmet needs based on a “surrogate endpoint,” rather than a direct measure of clinical benefit.The combo therapy also received FDA’s breakthrough therapy designation (BTD) based on the safety and clinical activity observed in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.A BTD designation is meant to expedite drug development for treating life-threatening and serious medical conditions by allowing increased FDA interactions and intensive guidance from the agency.Sushil Patel, CEO of Replimune, said, "Today is an important milestone for Replimune and for the melanoma community as we are one step closer to having another potential treatment available for patients who have limited options after progressing on anti-PD1 containing regimens.”The biopharma said patients are&nbsp;currently being enrolled for the confirmatory late-stage study, dubbed IGNYTE-3 trial.<figure class="image"><a href="https://stocktwits.com/symbol/REPL"><img style="aspect-ratio:635/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/repl_sentiment_0c14327fe5.png" alt="repl-sentiment.png" width="635" height="137"></a><figcaption>REPL sentiment and message volume November 22, 2024, as of 3:25 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment inflected higher from ‘neutral’ (46/100) a day ago to ‘bullish’ (57/100), with message volume rising to ‘extremely high.’Replimune stock climbed 19.37% in Thursday’s after-hours session to $13.19, its highest level in a little over a year. The stock has gained 31.08% for the year-to-date period.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/reddit-stock-drops-on-insider-sales/cJI5NjxRXx">Reddit Stock Pulls Back From Record Highs After Tencent Cuts Stake Yet Again: Retail Turns Apprehensive</a>

Replimune's RP1+Opdivo combo therapy gets breakthrough therapy designation. 

Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat

Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.

Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024...

Replimune Group announces inducement grants under Nasdaq listing rule

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest REPL News

REPLReplimune Group Inc